<DOC>
	<DOCNO>NCT00719862</DOCNO>
	<brief_summary>The Purpose study determine one allergy medication ( 0.15 % azelastine hydrochloride ) effective Placebo alone</brief_summary>
	<brief_title>A Study Evaluate Safety &amp; Effectiveness Nasal Spray Treat Seasonal Allergies</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<criteria>Male female patient 12 year age old 2 year history moderate severe seasonal allergic rhinitis Must generally good health Must meet minimum symptom requirement , specify protocol Must willing able provide inform consent participate study procedure Positive skin test prevalent fall allergen On focused Nasal Examination , presence nasal mucosal erosion , nasal ulceration , nasal septal perforation either screen visit randomization visit disqualify subject study . Other nasal disease ( ) likely affect deposition intranasal medication , sinusitis , rhinitis medicamentosa , clinically significant polyposis , nasal structural abnormality . Nasal Surgery sinus surgery within previous year Chronic sinusitismore 3 episode year Planned travel outside study area study period The use investigational drug within 30 day prior screen . No investigational product permit use conduct study . Presence hypersensitivity drug similar azelastine either sorbital sucralose ( Splenda brand sweetener ) Women pregnant nursing Women childbearing potential abstinent practice medically acceptable method contraception Respiratory tract infection within 14 day prior screen Respiratory tract infection require antibiotic treatment 14 day prior screen Asthma ( exception mild , intermittent asthma ) . Subjects mild , intermittent asthma require shortacting inhaled bronchodilator ( often tha twice week ) nocturnal awaken result asthma eligible enrollment Significant pulmonary disease include COPD Clinically significant arrythmia symptomatic cardiac condition A known history alcohol drug abuse within last 2 year Existence surgical medical condition physical laboratory finding , opinion investigator sponsor 's medical monitor , might significantly alter absorption , distribution , metabolism , excretion study drug ; might significantly affect subject 's ability complete trial ; safety trial Clinically relevant abnormal physical finding , opinion investigator , would interfere objective study may preclude compliance study procedure .</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>